Clinicians urge PrEPX participants to continue their PrEP
Clinicians are urging participants in the PrEPX research study to continue their PrEP* medication, following reports that a study participant tested positive to HIV while being enrolled in the PrEPX trial.
PrEPX is a population-based HIV prevention study examining how expanding the use of PrEP* medication impacts the rates of new HIV infections in Victoria.
“It is important that people enrolled in the PrEPX study continue to take their medication,” said Lead researcher, A/Prof Edwina Wright. “When taken daily PrEP may reduce HIV transmission by up to 99 per cent."
“If concerned, participants should talk directly to the doctor or nurse monitoring them throughout the trial.
“Our researchers are reviewing the clinical details of the participant who tested positive. There has been no confirmed case in Australia of a person on PrEP being infected with drug-resistant HIV," she said.
In Victoria the PrEPX study is sponsored by the State Government, Victorian AIDS Council (VAC) and Alfred Health.
Enrolled PrEPX participants: If concerned speak with the doctor or nurse monitoring you throughout the study.
*Pre-Exposure Prophylaxis (PrEP) is medication taken daily to prevent HIV infection in people who are at high risk.
_500_333.png)
